Research To Practice | Oncology Videos

Featuring perspectives from Dr Nikhil I Khushalani and Dr Anna C Pavlick , including the following topics: Introduction: Why Did It Take So Long? (0:00) Cutaneous Squamous Cell Carcinoma — Dr Khushalani (13:47) Basal Cell Carcinoma — Dr Pavlick (39:57) CME information and select publications

Featuring perspectives from Dr Peter C Enzinger, including the following topics: Introduction (0:00) Case: A man in his mid 60s with HER2-positive metastatic squamous cell carcinoma of the esophagus develops progressive disease after treatment with 5-FU/cisplatin/trastuzumab; PD-L1 CPS 10 — Eric H Lee, MD, PhD (12:16) Case: A man in his early 50s with HER2-negative, microsatellite stable esophagea...

Featuring perspectives from Dr Naval Daver, including the following topics: Introduction: Biology, Classification, p53, Magrolimab (0:00) Case: A man in his early 70s with acute myeloid leukemia (AML) with a TP53 mutation, myelodysplastic syndromes (MDS)-related changes and complex cytogenetics who received CPX-351receives azacitidine/venetoclax and is now in palliative care — Anna Halpern, MD (9:...

Featuring perspectives from Dr Toby A Eyre and Dr Brad S Kahl , including the following topics: Introduction: Mantle Cell Lymphoma (MCL) and the General Medical Oncologist (0:00) Sequencing of Therapy for MCL: 2009-2025 (11:19) Cases and Questions from the Community (36:44) Case: A man in his early 80s with relapsed/refractory MCL with "brain fog" on zanubrutinib — Zanetta S Lamar, MD (56:07) CME...

Featuring an interview with Dr Joseph Mikhael , including the following topics: Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy for newly diagnosed multiple myeloma (MM) (0:00) KRd versus elotuzumab and KRd for transplant-eligible patients with newly diagnosed MM (10:47) Subgroup analysis of patients with 1q21 and other cytogenetic a...

Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 2: Novel Approaches to Adjuvant Treatment for Localized NSCLC CME information and select publications

Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 1: The Evolving Role of Neoadjuvant Therapy for Localized Non-Small Cell Lung Cancer (NSCLC) CME information and select publications

Featuring perspectives from Dr Jamie Chaft and Dr John V Heymach , including the following topics: Introduction: Patient Involvement in Adjuvant and Neoadjuvant Treatment Decisions (0:00) Targetable Treatment for Localized Disease (11:49) Immunotherapy for Localized Disease (35:57) CME information and select publications

Featuring an interview with Dr Michael Pishvaian , including the following topics: Importance of next-generation sequencing as part of the diagnostic workup for metastatic pancreatic cancer (0:00) Optimal treatment selection for patients with germline BRCA mutation-positive pancreatic cancer (3:32) NAPOLI-3 Phase III trial of liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin (NAL...

Featuring an interview with Dr Matthew Matasar , including the following topics: Rationale for the evaluation of anti-CD20 x CD3 bispecific antibodies in the treatment of non-Hodgkin lymphoma (NHL) (0:00) Incidence, severity and time course of cytokine release syndrome, neurotoxicity/ICANS and other adverse events associated with bispecific antibodies; recommended mitigation and management protoco...

Featuring perspectives from Dr Kathleen N Moore, including the following topics: Introduction: SOLO-1 Trial (0:00) Case: A woman in her mid 50s with a germline BRCA1 mutation who received IV/IP chemotherapy followed by olaparib maintenance experiences disease recurrence — Neil Morganstein, MD (15:58) Case: A woman in her late 50s with a germline BRCA2 mutation undergoes surgery and chemotherapy fo...

Featuring a slide presentation and related discussion from Dr Philippe Moreau, including the following topics: General overview of anti-CD38 antibodies in therapy for multiple myeloma (MM) (0:00) Anti-CD38 antibodies as part of first-line therapy for transplant-ineligible patients with MM (2:35) Quadruplet versus triplet induction regimens with anti-CD38 antibodies for newly diagnosed, transplant-...

Featuring an interview with Prof Philippe Moreau , including the following topics: Perspectives on efficacy outcomes with and toxicity profiles of daratumumab and isatuximab (0:00) Selection of an anti-CD38 antibody for initial treatment of multiple myeloma (MM) (7:28) Approach to maintenance therapy for transplant-eligible patients with MM (15:47) Management of MM in older patients; treatment app...

Featuring perspectives from Dr Kristen K Ciombor and Dr J Randolph Hecht , including the following topics: Introduction (0:00) Case: A woman in her early 80s with KRAS-mutated, HER2-positive metastatic colorectal adenocarcinoma — Zanetta S Lamar, MD (14:29) Case: A man in his late 70s with metastatic KRAS G12C-mutated rectal adenocarcinoma treated with third-line sotorasib/panitumumab — Georges Az...

Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer | Faculty Presentation 2: Targeted Treatment for R/R mCRC — J Randolph Hecht, MD CME information and select publications

Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer | Faculty Presentation 1: Nontargeted Treatment Approaches for Relapsed/Refractory (R/R) Metastatic Colorectal Cancer (mCRC) — Kristen K Ciombor, MD, MSCI CME information and select publications

Featuring an interview with Prof Naveen Pemmaraju , including the following topics: Case: A woman in her mid 20s with classic blastic plasmacytoid dendritic cell neoplasm (BPDCN) who responded to combination hyper-CVAD/venetoclax (0:00) Defining and diagnosing BPDCN (5:17) Presentation, prevention and management of capillary leak syndrome (7:56) Targeting CD123 in BPDCN (12:53) Case: A man in his...

Featuring a slide presentation and related discussion from Prof Naveen Pemmaraju , including the following topics: Overview of blastic plasmacytoid dendritic cell neoplasms (0:00) Tagraxofusp: Development of the first FDA-approved targeted therapy for BPDCN (9:07) Integration of pivekimab sunirine into the management of BPDCN (20:31) Emerging novel therapies for patients with BPDCN and current rol...

Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, moderated by Dr Mascarenhas , including the following topics: Introduction (0:00) Clinical Decision-Making for Patients with Myelofibrosis (MF) — Dr Bose (2:27) Management of MF in Special Patient Populations — Dr Mascarenhas (19:26) Future Directions in the Management of MF — Dr Kuykendall (48:09) CME information and selec...

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer | Faculty Presentation 2: Current and Future Role of Nonbiomarker-Based Strategies for Patients with Metastatic BRCA-Negative TNBC — Hope S Rugo, MD CME information and select publications

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer | Faculty Presentation 1: Biomarker-Based Decision-Making for Patients with Metastatic BRCA-Negative, Triple-Negative Breast Cancer (TNBC) — Tiffany A Traina, MD, FASCO CME information and select publications

Featuring perspectives from Dr Hope S Rugo and Dr Tiffany Traina , including the following topics: Introduction: "Isn't Oncology Depressing?" (0:00) Checkpoint Inhibitors (13:37) Antibody-Drug Conjugates (30:04) HER2-Low Disease (54:25) Other Agents Under Development (59:54) CME information and select publications

Featuring an interview with Dr Paul G Richardson , including the following topics: Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00) Similarities and differences between iberdomide, mezigdomide and standard immunomodulatory drugs (7:14) Compassionate use of melflufen and belantamab mafodotin (12:0...

Featuring a slide presentation and related discussion from Dr Paul G Richardson, including the following topics: Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00) Published efficacy and safety findings with iberdomide-containing combination regimens from the Phase I/II CC-220-MM-001 study (6:30) E...

Featuring an interview with Dr Debra Richardson , including the following topics: Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors (0:00) Activity, safety and ongoing investigation of tumor treating fields in combination with chemotherapy for advanced ovarian cancer (5:12) ASCO and SGO guidance on the nationwide shortages of carboplatin and cisplatin (9:2...